We report a series of new in vitro and in vivo data proving the selective antitumor activity of our somatostatin structural derivative, TT-232. In vitro, it inhibited the proliferation of 20 different human tumor cell lines in the range of 50-95% and induced a very strong apoptosis. In vivo was not toxic at a dose of 120 mg/kg of b.w. in mice. Long-term incubation (24 h) of tumor cells with TT-232 caused significant inhibition of tyrosine kinases in good correlation with the apoptosis-inducing effect. The level of p53 or KU86 did not change following TT-232 treatment, suggesting a p53-independent apoptotic effect. Preincubation of human breast cancer cells (MDA-MB-453) with TT-232 for 2 h decreased the growth factor receptor autophosphorylation. All of these data suggest that TT-232 is a promising and selective antitumor agent.
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We report a series of new in vitro and in vivo data proving the selective antitumor activity of our somatostatin structural derivative, TT-232. In vitro, it inhibited the proliferation of 20 different human tumor cell lines in the range of 50-95% and induced a very strong apoptosis. In vivo w. of TT-232 for 3 weeks resulted in 60% decrease in tumor volume and 100% survival even after 60 days, while 80% of nontreated animals perished. We have demonstrated that TT-232 did not bind to the membrane preparation of rat pituitary and cortex and had no antisecretory activity. was not toxic at a dose of 120 mg/kg of b.w. in mice. Long-term incubation (24 h) of tumor cells with TT-232 caused significant inhibition of tyrosine kinases in good correlation with the apoptosis-inducing effect. The level of p53 or KU86 did not change following TT-232 treatment, suggesting a p53-independent apoptotic effect. Preincubation of human breast cancer cells (MDA-MB-453) with TT-232 for 2 h decreased the growth factor receptor autophosphorylation. All of these data suggest that TT-232 is a promising and selective antitumor agent.
Somatostatin, a natural tetradecapeptide, inhibits both the growth hormone release (1) and various other endocrine secretions (i.e., glucagon, insulin, and gastrin) (2, 3) . It inhibits or regulates several cell functions as well, and it has also been discovered to be an important endogen antiproliferative agent (4) (5) (6) (7) (8) . In recent years, many potent somatostatin analogs have been developed as antisecretory and antiproliferative hormones (Sandostatin or Octreotide of Sandoz, Somatuline of Biomeasure, and RC-160 of Debiopharm), acting longer than the native hormone, and they have been used in the treatment of hormone dependent tumors, but their administration as antitumor agents is limited because of their side effects (9) (10) (11) (12) (13) .
Lots of efforts have been made to obtain a tumor selective somatostatin analog but without any significant success.
Previously we reported a unique, potent tumor-selective somatostatin analog of a five-residue ring structure: D-PheCys-Tyr-D-Trp-Lys-Cys-Thr-NH2 (TT-232). This analog had practically no growth hormone (GH) release inhibitory activity either in superfused rat pituitary cells or in rats in vivo. TT-232 showed a strong antiproliferative effect both in vitro and in vivo (14) (15) (16) and induced apoptosis in a pancreatic tumor cell line (17) as demonstrated for other somatostatin analogs (18, 19) .
This compound has a special structure, its backbone behaving very differently from that observed in the GH active analogs (20) . TT-232 inhibited tyrosine kinase activity of some human colon tumor cell lines, and this inhibition correlated well with the inhibition of cell proliferation (14) . When incubating colon tumor cells with this peptide for short periods of time (10-100 min), no significant inhibition of tyrosine kinases was observed, but a significant stimulation of tyrosine phosphatases could be detected with a biphasic dose dependency (21) .
TT-232 has been tested on 60 various human tumor cell lines by the National Cancer Institute of the National Institutes of Health. It was found that at a higher dose (100 ,M) TT-232 had a very strong antiproliferative effect on 58 cell lines, while TT-248, one of our "traditional type" somatostatin analogs, which in other respect showed similar biological effects to that of RC-160 or Sandostatin had practically no effect on the same cell lines (unpublished results). Somatostatins activate protein kinase C and stimulate the inositol triphosphate level in colon tumor cells following a long term incubation (22, 23) . So it may be concluded that TT-232 interacts with various signaling pathways in tumor cells, and the interrelationship of these pathways may determine the antiproliferative effect via the induction of apoptosis and the inhibition of mitosis. In vivo, TT-232 has been very effective in the Lewis lung tumor, spleen-liver metastasis model in mice, causing a 70% inhibition in the number of metastasis (17) .
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 248) were synthesized in our laboratory as described earlier (14) . D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160) (24) In Vitro Antitumor Assays. Approximately 350,000 cells were cultured in 2 ml of culture medium in a well (6-well plates were used, Greiner, Nurtingen, Germany) and incubated for 24 h with different doses of TT-232 in the absence of fetal calf serum. After trypsinization and dispersion, the cells were dyed with trypan blue and counted in a hemocytometer.
Study of Apoptosis. Tumor cells (105/ml) were treated with various doses of TT-232 for 8-24 h. Cell count was determined regularly at 24, 48, and 72 h. Triplicate determinations per dose and time points were performed both in cases of treated and untreated cell cultures. Three coverslips per dose and time point were fixed in ethanol/acetic acid (3:1) and stained with hematoxylin and eosin. The specific morphology of apoptotic cells (nuclear pyknosis or karyorrhexis, cytoplasmic shrinkage, apoptotic bodies in the cytoplasm of nonapoptotic tumor cells) was identified by the hematoxylin and eosin staining and by routine transmission electromicroscopic investigation. The ratio of apoptotic and mitotic figures was determined by counting 500 cells. Immunohistochemical reaction using Apop-Tag kit (26) (Oncor) was applied to detect in situ the new 3'-OH DNA ends characteristic to apoptosis.
Tyrosine Kinase Activity Assay. The assay was carried out as described earlier (27) Colon 26 tumor fragments (from Karolinska Institute, Stockholm) were s.c. transplanted into BALB/C inbred mice; B16 melanoma cell suspension (also from Karolinska Institute) was transplanted into BDF1 hybrid mice; S180 sarcoma tumor fragments (Chester Beatty Cancer Research Institute, London) were transplanted into Swiss outbred mice. Ten animals were in each group (21-23 g ). The i.p. treatment with different doses of TT-232 [15, 150 and 750 ,ug/kg body weight (b.w.) twice a day] was initiated 1 day after the tumor transplantation and continued till the first animal perished. Lifetime changes were compared with nontreated tumor-bearing animals, and the size of solid tumors was measured with a caliper two or three times weekly. Tumor volume was calculated using the formula V = a2 X b X ir/6 where a means the shorter diameter, which is perpendicular to b the longest diameter of a tumor (28) .
Human MDA-MB-231 breast and PC-3 prostate tumor cell lines obtained from American Type Culture Collection were xenografted in immunodeficient mice. Female 6-7-week-old inbred CBA/Ca mice from our specified pathogen-free breeding were used. Pieces of adequate tumor tissue (1-1.5 mm3)
were transplanted s.c. Development of immunosuppression in normal CBA/Ca mice was carried out by thymectomy, whole body irradiation (9.5 Gy), and bone marrow transplantation. Two or three weeks after tumor transplantation, tumors had grown to a volume of approximately 0.1 cm3, the mice were randomized and divided into experimental groups (10 mice per group). TT-232 was administered in a saline vehicle containing 0.1% acetic acid s.c. on the side opposite of the tumor once or twice daily at doses of 0.25, 0.5, 5, 10, and 20 mg/kg of b.w. Treatments of breast and prostate tumor-bearing animals with TT-232 were started on days 21 and 18, respectively, after tumor transplantation. Drug administration was applied continuously for 30 and 24 days, respectively. Tumors were measured two or three times weekly, and their volumes were calculated as described above. The effect of TT-232 treatments on the changes in lifetime was compared with that of the nontreated tumor-bearing animals as well.
Gastric Acid Secretion. Experiments were carried out on male Wistar rats (Iffa Credo) weighing 250-350 g provided with a Thomas cannula. Gastric juice was collected in 20-min fractions. The volume was measured, and the acid concentration and output were calculated after titration to pH 7 with 0.01 M NaOH. The basal level was taken as the mean of the three first 20-min samples. After the basal collection period (t = 0), a venous infusion of RC-160 (2 ,tg/kg), TT-232 (1.78 p,g/kg), TT-248 (2.28 ,ug/kg), or NaCl was performed for 3 h in a tail vein. One hour later (t = 60 min), while continuing the peptide infusion, gastric secretion was stimulated by a venous step-dose infusion of pentagastrin (0.25; 1 and 4 ,ug/kg) each for 40 min.
Study of Phosphotyrosine Content of Tumor Cells. MDA-MB-453 attached cells (2 x 105) (obtained from American Type Culture Collection) were treated with TT-232 or Sandostatin (0.1, 1, or 30 ,ug/ml) for 2 h and then scraped in 200 ,ul of lysis buffer (50 mM Hepes-150 mM NaCl/1.5 mM MgCl2/1 mM EGTA/10% glycerol/1% Triton X-100/1 mM phenylmethyl sulfonyl fluoride/10 ,ug/ml aprotinin/100 mM NaF/ 40 mM sodiumvanadate/ 5 mM Na4P207; all from Sigma). After 10 min on ice, the samples were centrifuged at 10,000 x g for 5 min. Seventy microliters of the supernatants was loaded to 7-15% gradient SDS-polyacrylamide gels, and electrophoresis was carried out as described (29) . Then electrotransfer of proteins on nitrocellulose was performed with a semi-dry blotting apparatus. The homogeneity of the protein transfer was controlled by Ponceau red staining. Phosphotyrosine content was revealed with a rabbit polyclonal antibody (at a 1:2000 dilution, 4 h). After the incubation with the second antibody (coupled to peroxidase, 1:20,000, 1 h) we used the immunochemiluminescent (ECL, Amersham) technique to visualize the bands of phosphotyrosine.
Toxicology Studies. Toxicology tests were carried out on male and female 6-7-week-old inbred CBA/Ca mice (22-25 g) from our specified pathogen-free breeding. The effect of different doses of TT-232 on survival and changes of body weights was tested for 2 weeks. The weight of different organs (heart, kidney, spleen, lung, liver, thymus, and uterus) was measured after 1-and 18-day treatments, respectively. Hematological studies, the analysis of bone marrow and cytology studies of different organs have been conducted as well.
Binding Studies. Binding studies were similar to that described before (30) . Stability Studies. The TT-232 content of the samples and formation of degradation products were followed by HPLC similarly to that described before (31) .
RESULTS
In Vitro Antiproliferative Effect of TT-232 on Human Tumor Cell Lines. Table 1 summarizes the results. TT-232 showed at least 50% antiproliferative effect on the examined cell lines; however, around 90% inhibition was achieved on breast carcinoma, prostate tumor, pancreatic, leukemia, melanoma, and gastric tumor cell lines. The effect of TT-232 and RC-160 was compared on the proliferation of PC-3 and HT-29 tumor cell lines. In a representative experiment on PC-3 cell line, TT-232 at 30 ,ug/ml dose showed a 90 ± 2% decrease in the number of tumor cells, but RC-160 resulted in only a 29 ± 2% decrease. On HT-29 cell line, the inhibition caused by TT-232 was about 72 ± 5%, and by RC-160 it was only 25 ± 3% when both dose, a 60% inhibition of tumor growth was achieved after 3 weeks of treatment (Fig. 3) Similar results were obtained with the rat cortex membrane preparation (data not shown). The fact that TT-232 did not bind either to the pituitary or to the brain receptors supports the previous finding that it has no effect on GH release. It has been reported that somatostatin inhibits the secretion of gastric acid (2) . We found that TT-232 did not inhibit the secretion of gastric acid; meanwhile results shown in Fig. 5 indicate that RC-160 and TT-248 two "traditional type" somatostatin analogs induced significant inhibition (90%) of gastric acid secretion when administered concurrently with different doses (0.25 ,tg/kg; 1 ,tg/kg; 4 ,tg/kg) of pentagastrin.
Mechanism of Action Studies with In the present work, we have demonstrated that TT-232 induces apoptosis (programmed cell death) in human colon (HT-29 and SW620), pancreatic (P818), leukemia (K-562), melanoma (WM 938/B, M-1, EP), and lymphoma (HT-58) tumor cell lines. The occurrence of apoptosis was followed by light-and electronmicroscopic as well as by immunohistochemical studies. In a representative experiment, the apoptotic index increased about 70 times in M-1 melanoma, 60 times in K-562 leukemia, 13 times in P818 pancreatic cells, seven times in HT-29 human colon tumor cells, and three times in PC-3 prostate tumor cells after 48 h incubation with 10 ,ug/ml of TT-232. In case of WM melanoma and EP melanoma cells, five and four times increase of apoptotic index has been observed after 24 h of incubation with the same dose of TT-232 (Fig. 5) . In some of the above described cell lines, further increasing the dose of TT-232 and the time of the incubation cell lysis occurred, which is probably due to a so far unknown mechanism resulting in destruction of the structure of cell membranes as a consequence of apoptosis.
We have investigated the effect of 10 and 30 ,ug/ml TT-232 on the level of wild-type p53 protein in P818 pancreatic and in HT-29 colon tumor cells and found no alterations in p53 level.
We also investigated the effect of TT-232 on the translocation of the KU86 protein from the cytosol to the nucleus (KU86 is a nuclear somatostatin receptor associated with p53) and found no significant. effect, suggesting that TT-232 induces apoptosis on a p53-independent way. TT-232 strongly inhibited tyrosine kinases (75%) after long term incubation (24 h) in SW620 colon tumor cell lines (Fig.  6 ), this effect correlates well with the antiproliferative and apoptosis inducing effect of TT-232.
In 
DISCUSSION
A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH release inhibitory activity (14) (15) (16) potent somatostatin analog that inhibits the tyrosine kinase signaling pathways and induces apoptosis, so it has great pharmaceutical perspectives. There are several small molecular tyrosine kinase inhibitors as potential drugs described in the literature, but their application is still limited because of the lack of selectivity (32) .
TT-232 has been selected from a big series of somatostatin analogs on the bases of structure-activity relationship studies regarding tyrosine kinase inhibitory and antiproliferative effect versus GH release inhibition (16) . In the present work, tyrosine kinase inhibitory studies were performed in human colon tumor cells where tyrosine kinase inhibition following a long term preincubation with the peptide correlated well with the dramatic inhibition of cell proliferation and the induction of apoptosis. We demonstrated now that TT-232 induces apoptosis in a series of cell lines suggesting that this peptide exerts its direct antitumor activity via signal transduction modulation and the induction of apoptosis.
Recently, the role of apoptosis in the regression of hormonetreated tumors has been widely studied (18, 33) . The role of tyrosine kinase inhibition in the induction of apoptosis has been well demonstrated as well, while our recent studies proved that an epidermal growth factor receptor-selective tyrosine kinase inhibitor induced a nonapoptotic programmed cell death but a nonselective tyrosine kinase inhibitor induced apoptosis (34) . Our finding that TT-232 results in a decrease of phosphotyrosine content in MDA MB-453 breast cancer cells, which contain Her3 receptor [the third member of the epidermal growth factor receptor family (35) ], supports our concept that TT-232 exerts its antiproliferative effect via the induction of programmed cell death. It has been reported in the literature that the nuclear protein KU86, which regulates p53 expression and apoptosis, is a somatostatin receptor (36) . We found that TT-232 had no effect on p53 and KU86, suggesting that its apoptotic effect is mediated independent of p53 (unpublished results).
The TT-232-induced inhibition of the growth-promoting tyrosine kinase signal could be coupled to the induction of the regular cell cycle with an apoptotic end. The long term tyrosine kinase inhibition and the previously found short term tyrosine phosphatase activation might be two separate effects of . Since we have demonstrated that TT-232 does not bind to the rat pituitary or the cortex, where all the known somatostatin receptor subtypes are expressed (37) , and has no GH release inhibitory and antisecretory activity, we believe that the antiproliferative and apoptosis inducing effect of TT-232 is mediated through a still unknown receptor. Known somatostatin analogs like RC-160 or Sandostatin exert their antiproliferative effect through the STR2 receptor, which is also present in the pituitary (38) . We are currently working on the isolation of the TT-232 receptor from tumor cells with affinity chromatography.
In in vivo experiments, relatively low doses of TT-232 have been applied, although our in vitro data show that for the dramatic antiproliferative and apoptosis-inducing effect, a critical dose-which also depends on the cell type-has to be reached. TT-232 had strong in vivo antitumor activity even at relatively low doses, which give us very good perspectives for the application of higher doses, reaching the critical threshold dose for the induction of apoptosis. Toxicity studies clearly demonstrated that TT-232 does not show toxic side effects even at a dose of 120 mg/kg of b.w.
In conclusion, TT-232 has good perspectives as a potent and selective antitumor drug.
